{"nctId":"NCT01576367","briefTitle":"Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease","startDateStruct":{"date":"2012-01-16","type":"ACTUAL"},"conditions":["Cryopyrin-associated Periodic Syndromes","Familial Cold Autoinflammatory Syndrome","Muckle-Wells Syndrome","Neonatal Onset Multisystem Inflammatory Disease"],"count":17,"armGroups":[{"label":"canakinumab","type":"EXPERIMENTAL","interventionNames":["Biological: ACZ885"]}],"interventions":[{"name":"ACZ885","otherNames":["Canakinumab"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Patients who completed the core CACZ885D2307 study (a patient is defined as having completed the core study if they completed the study up to and including the EOS visit with no major protocol deviations in the core).\n2. Male and female patients that are ≥ 1 year of age at the time of the roll-over visit.\n3. Parent or legal guardian written informed consent must be obtained before any assessment in the extension CACZ885D2307E1 study is performed.\n\nExclusion criteria:\n\n1. Patients for who continued treatment in the CACZ885D2307E1 extension study is not considered appropriate by the treating physician.\n2. Patients who discontinued from the core CACZ885D2307 study\n\nOther protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"4 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Participants Without Disease Relapse as Determined by the Physician's Global Assessment of Autoinflammatory Disease Activity, Assessment of Skin Disease and Serological Inflammation Markers.","description":"Disease relapse following complete response is defined as inflammation markers: C-Reactive Protein (CRP) and/or Serum Amyloid A (SAA) result \\> 30 mg/L AND Physician's Global Assessment of Autoinflammatory Disease Activity \\> minimal or Physician's Global Assessment \\>= minimal AND Skin Disease Assessment \\> minimal. Physician's Global Assessment of Autoinflammatory Disease Activity and Skin Disease Assessment (urticarial skin rash) are completed by the investigator using a 5 point rating scale: absent, minimal, mild, moderate and severe.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity of Canakinumab (ACZ885). Number of Participants With Anti-canakinumab Antibodies","description":"Immunogenicity assessment included determination of anti-canakinumab (ACZ885) antibodies in serum samples using BIAcore system, with detection based on surface plasmon resonance technique.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Core Study Baseline) in C--Reactive Protein (CRP) and Serum Amyloid A (SAA) Concentrations","description":"CRP and SAA were used as serologic inflammatory markers. The target level concentrations for CRP and SAA was ≤15 mg/L and ≤10 mg/L, respectively. Negative change in concentration of inflammatory markers indicated improvement.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.4","spread":"6.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.7","spread":"35.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.8","spread":"14.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"10.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.3","spread":"11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.4","spread":"30.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-54.4","spread":"133.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-79.1","spread":"224.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.8","spread":"158.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.2","spread":"47.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.4","spread":"60.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-58.5","spread":"183.6"}]}]}]},{"type":"SECONDARY","title":"Frequency Counts of Physician's Global Assessment of Autoinflammatory Disease and Skin Disease","description":"Participants were assessed based by physician on Physician's Global Assessment measured on a 5--point scale for auto inflammatory disease activity as: 0 = None/absent; 1 = Minimal; 2 = Mild; 3 = Moderate; 4 = Severe","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Vaccination Cases With Protective Antibody Levels Following Immunization With Inactivated Vaccines","description":"Participants who received any inactivated vaccines during the study were assessed for their ability to attain protective antibody levels against the vaccine (antigen) post immunization. Participants vaccinations were not assessed for a response if the antibody titre was already sufficient at pre-dose and maintained during the study.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":17},"commonTop":["Diarrhoea","Nasopharyngitis","Vomiting","Pyrexia","Headache"]}}}